Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis: Clin Infect Dis

Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis: Clin Infect Dis

We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen cou...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2020, Vol.70 (5), p.943-946
Main Authors: Gantner, P., Hessamfar, Mojgan, Souala, M. F., Valin, N., Simon, A., Ajana, F., Bouvet, E., Rouveix, E., Cotte, L., Bani-Sadr, F., Hustache-Mathieu, L., Lebrette, M. G., Truchetet, F., Galempoix, J. M., Piroth, L., Pellissier, G., Muret, P., Rey, D.
Format: Article
Language:eng
Subjects:
Life Sciences
Santé publique et épidémiologie
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated an elvitegravir–cobicistat–emtricitabine–tenofovir alafenamide single-tablet regimen for human immunodeficiency virus postexposure prophylaxis. The completion rate and adherence were good, and the tolerance was acceptable; no seroconversion was observed. We confirm that this regimen could be appropriate for postexposure prophylaxis.
ISSN:1058-4838
1537-6591